Background {#Sec1}
==========

Colorectal polyps exhibit different morphologic features with flat, depressed, serrated, sessile or pedunculated shapes and are often regarded as benign protrusions of the colon and rectum mucosa \[[@CR1], [@CR2]\]. There are many types of colorectal polyps, such as hyperplastic polyps and adenomatous polyps \[[@CR2], [@CR3]\]. Despite the low malignant potential, the possible malignant change in colorectal polyps is related to the presence of colorectal cancer (CRC). For instance, some colonic polyps exist in patients with familial adenomatous polyposis (FAP) who are prone to cancer \[[@CR4]\].

The 5,10-methylenetertahydrofolate reductase (*MTHFR*) gene is essential for the folate cycle and homocysteine metabolism \[[@CR5]\]. rs1801133 (C677T) and rs1801131 (A1298C) are two common functional polymorphisms within the *MTHFR* gene \[[@CR6], [@CR7]\]. *MTHFR* rs1801133 and rs1801131 polymorphisms were reportedly associated with an enhanced risk of colorectal adenomatous polyp patients in the Korean population \[[@CR8]\]. However, no association between the *MTHFR* rs1801133 polymorphism and colorectal adenomatous polyp susceptibility was reported in the Dutch \[[@CR9]\] or Japanese population \[[@CR10]\]. These findings merit a comprehensive evaluation.

To the best of our knowledge, only one reported meta-analysis \[[@CR6]\] of the association between *MTHFR* rs1801131 and colorectal adenoma and three meta-analyses \[[@CR6], [@CR11], [@CR12]\] of *MTHFR* rs1801133 and colorectal adenoma were found during the database searching. However, the conclusion remains inconsistent. Additionally, we failed to retrieve a meta-analysis specific for the association between *MTHFR* polymorphisms and the susceptibility to both hyperplastic/adenomatous polyps. Herein, we have made an attempt to better investigate the potential genetic role of *MTHFR* rs1801133 and rs1801131 polymorphisms in the risk of colorectal polyps through an updated meta-analysis.

Methods {#Sec2}
=======

Database searching and screening process {#Sec3}
----------------------------------------

Two authors (MS and JZ) gathered the relative records through searching the databases, namely, PubMed, WOS (Web of Science), and EMBASE (Excerpta Medica Database), prior to March 2018. The PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines were followed \[[@CR13]\]. The search terms used with the databases are shown in Additional file [1](#MOESM1){ref-type="media"}: Table S1. We independently excluded duplicate and ineligible records based on the following criteria: reviews, mouse data, case reports or trials, meta-analyses, meeting or conference abstracts, other genes, non-SNP or nonpolyp data, or missing genotype data for rs1801133 or rs1801131. Then, the remaining studies were included as eligible case-control studies.

Data extraction and quality assessment {#Sec4}
--------------------------------------

We carefully extracted the data from the above selected studies. The chi-squared test was applied for the calculation of the *P* value of HWE (Hardy-Weinberg Equilibrium). The included studies should provide the genotype frequency data of the control group, which also must be in line with the requirement of HWE. We summarized the main features of the included studies, such as first author name, publication year, polymorphism genotype frequency, country, ethnicity, genotyping assay, and *P* value of HWE. We also utilized quality assessment (Newcastle-Ottawa Scale, NOS) to determine the quality score of the enrolled studies. Studies with poor quality (NOS score less than five) were excluded.

Association test {#Sec5}
----------------

We obtained the *P*~association~, risk ratios (RRs) and 95% confidence intervals (CIs) through the association test. The *P*~heterogeneity~ value of Cochran's Q statistic \> 0.1 or I^2^ value \< 50% led us to use a fixed-effects model. Six genetic models were used: allele T vs. allele C for rs1801133, allele C vs. allele A for rs1801131 (allele); TT vs. CC, CC vs. AA (homozygote); CT vs. CC, AC vs. AA (heterozygote); CT + TT vs. CC, AC + CC vs. AA (dominant); TT vs. CC + CT, CC vs. AA+AC (recessive); carrier T vs. carrier C, carrier C vs. carrier A (carrier).

Heterogeneity source analysis {#Sec6}
-----------------------------

We also carried out a sensitivity analysis and subgroup analyses for all genetic models to evaluate the data stability and source of heterogeneity. Briefly, we omitted each included study in turn to acquire a group of meta-analysis estimations. The omitted study was regarded as the probable heterogeneity source if we detected an obvious alteration of RR and 95% CI value. Subgroup analyses were also carried out, taking the factors of country, ethnicity (Caucasian/Asian) and disease type (hyperplastic polyps/ adenomatous polyps) into consideration.

Publication bias analysis {#Sec7}
-------------------------

We conducted both Begg's test (Begg's funnel plot) and Egger's test (Egger's publication bias plot) to evaluate possible publication bias. The absence of a large publication bias was considered when the *P* values of Begg's test and Egger's test were \> 0.05. STATA/SE software (StataCorp, USA) was utilized for all the above tests.

Results {#Sec8}
=======

Identification of eligible studies {#Sec9}
----------------------------------

We initially identified a total of 153 records by searching three databases, namely, PubMed (*n* = 22), WOS (*n* = 83), and EMBASE (*n* = 48). After excluding duplicate records, a total of 115 records were filtered by our criteria. The following 88 records were excluded: reviews (*n* = 31), mouse data (n = 4), case reports or trials (*n* = 7), meta-analyses (*n* = 6), meeting or conference abstracts (n = 8); other genes (*n* = 9), non-SNP or nonpolyp data (*n* = 23). Subsequently, twenty-seven full-text articles were evaluated for eligibility. Five articles lacked control or T/T genotype data. Finally, a total of twenty-two articles \[[@CR8]--[@CR10], [@CR14]--[@CR32]\] were selected. We listed the characteristics of eligible studies in the meta-analysis (Table [1](#Tab1){ref-type="table"}). The genotype contributions of all controls in the studies fulfilled the principle of HWE. We found that one article contained two case-control studies, namely, the genotype distribution data in both adenomatous and hyperplastic polyps. In total, twenty-three case-control studies were ultimately included for the overall meta-analysis of *MTHFR* rs1801133, and ten case-control studies were included for that of *MTHFR* rs1801131. In addition, one study in which the TT genotype frequency of case and control groups for rs1801133 equaled zero was not included in the meta-analysis under the TT vs. CC (homozygote) and TT vs. CC + CT (recessive) models. The PRISMA-based analysis flowchart is shown in Fig. [1](#Fig1){ref-type="fig"}. None of the included studies exhibited poor quality (all NOS scores were larger than five).Table 1Main features of eligible studies for pooled analysisFirst authorYearNOSPolymorphismCaseDisease typeControlCountryEthnicityGenotyping assay*P* ~*HWE*~A/AA/BB/BA/AA/BB/BAl-Ghnaniem \[[@CR14]\]20077rs180113322121adenomatous polyps41296UKCaucasianPCR-RFLP0.784rs18011331133hyperplastic polyps41296UKCaucasianPCR-RFLP0.784rs180113118125adenomatous polyps47263UKCaucasianPCR-RFLP0.799rs1801131872hyperplastic polyps47263UKCaucasianPCR-RFLP0.799Ashktorab \[[@CR15]\]20076rs18011331840colorectal polyps3050USACaucasianPCR-RFLP0.649Beckett \[[@CR16]\]20155rs180113329207adenomatous polyps889118AustraliaCaucasianPCR-RFLP0.421rs180113128226adenomatous polyps1018313AustraliaCaucasianPCR-RFLP0.460Chen \[[@CR17]\]19988rs180113310212630adenomatous polyps32332466USACaucasianPCR-RFLP0.234Chiang \[[@CR18]\]20157rs180113344260adenomatous polyps917318ChinaAsianPCR-RFLP0.553de Vogel \[[@CR19]\]20116rs1801133947714135adenomatous polyps44633563708NorwayCaucasianReal-time PCR0.933Delgado \[[@CR20]\]20018rs18011336197adenomatous polyps345224MexicoCaucasianPCR-RFLP0.625Giovannucci \[[@CR21]\]20036rs180113315716849adenomatous polyps299325101USACaucasianPCR-RFLP0.401rs180113118616524adenomatous polyps36929957USACaucasianPCR-RFLP0.740Goode \[[@CR22]\]20047rs180113323619658adenomatous polyps25923867USACaucasianPCR-RFLP0.281Hazra \[[@CR23]\]20077rs180113321724563adenomatous polyps22923264USACaucasianNA0.658rs180113127821148adenomatous polyps26421946USACaucasianNA0.951Hirose \[[@CR24]\]20058rs180113318220367adenomatous polyps399496155JapanAsianPCR-RFLP0.966Yi \[[@CR8]\]20066rs1801133554adenomatous polyps240KoreaAsianPCR-RFLP0.221rs18011311031adenomatous polyps330KoreaAsianPCR-RFLP0.414Levine \[[@CR25]\]20007rs180113325616352adenomatous polyps26319849USACaucasianPCR-RFLP0.193Lightfoot \[[@CR26]\]20088rs180113313513241adenomatous polyps13013927UKCaucasianTaqman drug metabolizing genotyping assays0.238rs180113115512429adenomatous polyps14013026UKCaucasianTaqman drug metabolizing genotyping assays0.590Marugame \[[@CR10]\]20008rs1801133839230adenomatous polyps8910526JapanAsianPCR-RFLP0.555Mitrou \[[@CR27]\]20067rs180113340537687adenomatous polyps40240789UKCaucasianPCR-RFLP0.340rs1801131383375104adenomatous polyps41538088UKCaucasianPCR-RFLP0.941Pufulete \[[@CR28]\]20037rs180113320132adenomatous polyps41296UKCaucasianPCR-RFLP0.784rs180113118125adenomatous polyps47263UKCaucasianPCR-RFLP0.799Ulrich \[[@CR29]\]19999rs180113325821950adenomatous polyps30326973USACaucasianPCR-RFLP0.260Ulrich \[[@CR30]\]20007rs1801133987226hyperplastic polyps29725871USACaucasianPCR-RFLP0.192van den \[[@CR9]\]20057rs180113334334679adenomatous polyps32530579NetherlandsCaucasianPCR-RFLP0.560Williams \[[@CR31]\]20137rs180113334488adenomatous polyps44429UKCaucasianPCR-RFLP0.822Yamaji \[[@CR32]\]20096rs1801133263325124adenomatous polyps219324120JapanAsianTaqMan PCR0.993rs180113145222832adenomatous polyps44119725JapanAsianTaqMan PCR0.609*A/A* C/C genotype of rs1801133, or A/A genotype of rs1801131, *A/B* C/T genotype of rs1801133, or A/C genotype of rs1801131, *B/B* T/T genotype of rs1801133, or C/C genotype of rs1801131, *NA* not available, *PCR-RFLP* polymerase chain reaction-restriction fragment length polymorphism, *HWE* Hardy-Weinberg Equilibrium, *NOS* Newcastle-Ottawa ScaleFIG. 1Flowchart of database searching and record screening process

Pooled analysis for *MTHFR* rs1801133 {#Sec10}
-------------------------------------

First, we carried out a meta-analysis to investigate the genetic relationship between *MTHFR* rs1801133 and colorectal polyp susceptibility. A total of twenty-three case-control studies with 8321 cases and 17,731 controls were included. As shown in Table [2](#Tab2){ref-type="table"}, compared with the control group, no increased risk of colorectal polyps was detected in the case group under the six genetic models, namely, allele T vs. allele C (*P* value in test of association =0.156); TT vs. CC (*P* = 0.454); CT vs. CC (*P* = 0.077); CT + TT vs. CC (*P* = 0.079); TT vs. CC + CT (*P* = 0.847); carrier T vs. carrier C (*P* = 0.322). We also conducted subgroup analyses by country, ethnicity (Caucasian/Asian) and disease type (hyperplastic polyps/adenomatous polyps). A similar nonsignificant genetic relationship was observed for all the models (all *P* \> 0.05, Table [2](#Tab2){ref-type="table"}). For example, there was no significant difference between the colorectal polyp cases and negative controls in the UK subgroup under the T vs. C allele (Table [2](#Tab2){ref-type="table"}, *P* = 0.886); TT vs. CC (*P* = 0.641); CT vs. CC (*P* = 0.351); CT + TT vs. CC (*P* = 0.511); TT vs. CC + CT (*P* = 0.436); or carrier T vs. carrier C (*P* = 0.831). In the subgroup analysis of "adenomatous polyps", we also did not observe a statistically significant association under the allele T vs. allele C (Table [2](#Tab2){ref-type="table"}, *P* = 0.153); TT vs. CC (*P* = 0.377); CT vs. CC (*P* = 0.113); CT + TT vs. CC (*P* = 0.098); TT vs. CC + CT (*P* = 0.696); and carrier T vs. carrier C (*P* = 0.331). We show the forest plots of the subgroup analyses based on disease type under the allele T vs. allele C model in Fig. [2](#Fig2){ref-type="fig"}. These results revealed that *MTHFR* rs1801133 does not appear to be significantly linked to susceptibility to colorectal polyps.Table 2Pooled analysis for the *MTHFR* rs1801133 polymorphismComparisonSubgroupSample sizeTest of associationStudiesCase/controlRRs (95% CIs)z*P*allele T vs. allele Coverall238321/17,7310.98 (0.95, 1.01)1.420.156UK61353/15170.99 (0.92, 1.07)0.140.886USA82863/43431.00 (0.95, 1.05)0.140.890Japan31369/19330.97 (0.91, 1.03)1.030.301Caucasian186868/15,6100.99 (0.96, 1.02)0.860.391Asian51453/21210.95(0.90, 1.01)1.530.126hyperplastic polyps2213/7020.99 (0.84, 1.16)0.130.897adenomatous polyps208086/16,9940.98 (0.95, 1.01)1.430.153TT vs. CCoverall228317/17,6960.97 (0.90, 1.05)0.750.454UK61353/15171.05 (0.85, 1.30)0.470.641USA72841/43081.01 (0.89, 1.14)0.110.913Japan31369/19330.95 (0.82, 1.11)0.610.540Caucasian176846/15,5750.99 (0.91, 1.08)0.310.760Asian51453/21210.92(0.80, 1.07)1.060.291hyperplastic polyps2213/7021.13 (0.77, 1.65)0.620.532adenomatous polyps208086/16,9940.97(0.77, 1.65)0.880.377CT vs. CCoverall238321/17,7310.97 (0.94, 1.00)1.770.077UK61353/15170.96 (0.89, 1.04)0.930.351USA82863/43430.99 (0.94, 1.04)0.440.663Japan31369/19330.94 (0.88, 1.01)1.670.094Caucasian186868/15,6100.98 (0.95, 1.01)1.110.269Asian51453/21210.94 (0.87, 1.00)1.920.055hyperplastic polyps2213/7020.88 (0.73, 1.07)1.270.205adenomatous polyps208086/16,9940.98 (0.95, 1.01)1.580.113CT + TT vs. CCoverall238321/17,7310.98 (0.95, 1.00)1.760.079UK61353/15170.98 (0.91, 1.06)0.660.511USA82863/43430.99 (0.95, 1.04)0.330.743Japan31369/19330.96 (0.91, 1.01)1.530.125Caucasian186868/15,6100.98 (0.96, 1.01)1.080.280Asian51453/21210.95 (0.90, 1.00)1.950.052hyperplastic polyps2213/7020.94 (0.80, 1.09)0.820.414adenomatous polyps208086/16,9940.98 (0.95, 1.00)1.650.098TT vs. CC + CToverall228317/17,6960.99 (0.92, 1.07)0.190.847UK61353/15171.09 (0.87, 1.36)0780.436USA72841/43081.02 (0.89, 1.16)0.230.822Japan31369/19331.01 (0.86, 1.18)0.080.934Caucasian176846/15,5751.00 (0.91, 1.09)0.070.944Asian51453/21210.98 (0.83, 1.15)0.280.780hyperplastic polyps2213/7021.23 (0.83, 1.84)1.040.299adenomatous polyps208086/16,9940.98(0.91, 1.84)0.390.696carrier T vs. carrier Coverall238321/17,7310.99 (0.96, 1.01)0.990.322UK61353/15170.99 (0.92, 1.07)0.210.831USA82863/43431.00 (0.95, 1.05)0.150.883Japan31369/19330.98 (0.91, 1.05)0.690.491Caucasian186868/15,6100.99 (0.96, 1.02)0.640.523Asian51453/21210.97 (0.90, 1.03)0.990.322hyperplastic polyps2213/7020.98 (0.82, 1.16)0.260.793adenomatous polyps208086/16,9940.99(0.96, 1.02)0.970.331*RRs* Risk ratios, *CIs* Confidence intervalsFIG. 2Subgroup analysis by disease type of association between *MTHFR* rs1801133 polymorphism and colorectal polyp risk under the allele T vs. allele C model

Pooled analysis for *MTHFR* rs1801131 {#Sec11}
-------------------------------------

Next, ten studies containing 2951 cases and 3527 controls were included in the meta-analysis of *MTHFR* rs1801131. Pooled analysis in the overall population (Table [3](#Tab3){ref-type="table"}) indicated a null association under all genetic models (all *P* \> 0.05). The results of the subgroup analysis for the UK, containing five studies of 1257 cases/1407 controls, suggested an increased risk in cases of colorectal polyps compared with controls under the genetic models of CC vs. AA (*P* = 0.032, RR = 1.27, 95% CIs = 1.02, 1.57) and CC vs. AA+AC (*P* = 0.036, RR = 1.27, 95% CIs = 1.02, 1.60). We showed the related forest plots in Figs. [3](#Fig3){ref-type="fig"} and [4](#Fig4){ref-type="fig"}. Nevertheless, no difference between cases and controls was observed in other subgroup meta-analyses (all *P* \> 0.05, Table [3](#Tab3){ref-type="table"}). For example, no increased or decreased risk of adenomatous polyps in cases was detected, compared with controls, under the allele C vs. allele A (Table [3](#Tab3){ref-type="table"}, *P* = 0.138); CC vs. AA (*P* = 0.114); AC vs. AA (*P* = 0.576); AC + CC vs. AA (*P* = 0.303); CC vs. AA+AC (*P* = 0.122); or carrier T vs. carrier C (*P* = 0.376). Thus, the C/C genotype of the *MTHFR* rs1801131 polymorphism may be related to an enhanced colorectal polyp risk in the UK population.Table 3Pooled analysis for the *MTHFR* rs1801131 polymorphismComparisonSubgroupSample sizeTest of associationStudiescase/controlRRs (95% CIs)z*P*allele C vs. allele Aoverall102951/35271.05 (0.99, 1.11)1.600.109UK51257/14071.08 (0.99, 1.17)1.790.073Caucasian82225/28581.04 (0.98, 1.10)1.220.222adenomatous polyps92934/34511.04 (0.99, 1.10)1.480.138CC vs. AAoverall102951/35271.15 (0.98, 1.35)1.690.091UK51257/14071.27 (1.02, 1.57)2.14**0.032**Caucasian82225/28581.14 (0.96, 1.35)1.500.133adenomatous polyps92934/34511.14 (0.97, 1.34)1.580.114AC vs. AAoverall102951/35271.02 (0.96, 1.08)0.630.528UK51257/14071.02 (0.93, 1.11)0.390.698Caucasian82225/28581.01 (0.95, 1.07)0.250.805adenomatous polyps92934/34511.02 (0.96, 1.08)0.560.576AC + CC vs. AAoverall102951/35271.03 (0.98, 1.08)1.130.258UK51257/14071.04 (0.97, 1.12)1.080.279Caucasian82225/28581.02 (0.97, 1.08)0.720.471adenomatous polyps92934/34511.03 (0.98, 1.08)1.030.303CC vs. AA + ACoverall102951/35271.15 (0.97, 1.36)1.640.100UK51257/14071.27 (1.02, 1.60)2.10**0.036**Caucasian82225/28581.14 (0.96, 1.36)1.490.135adenomatous polyps92934/34511.14 (0.97, 1.35)1.550.122carrier C vs. carrier Aoverall102951/35271.03 (0.97, 1.09)0.960.336UK51257/14071.04 (0.96, 1.14)1.000.318Caucasian82225/28581.02 (0.96, 1.09)0.680.499adenomatous polyps92934/34511.03 (0.97, 1.09)0.880.376*PB* Population-based control, *HB* Hospital-based control, *RRs* Risk ratios, *CIs* Confidence intervalsBold entries are significantFIG. 3Subgroup analysis by country of association between *MTHFR* rs1801131 polymorphism and colorectal polyp risk under the CC vs. AA modelFIG. 4Subgroup analysis by country of association between *MTHFR* rs1801131 polymorphism and colorectal polyp risk under the CC vs. AA+AC model

Heterogeneity, publication bias and sensitivity analysis {#Sec12}
--------------------------------------------------------

In addition, we evaluated the between-study heterogeneity and did not detect remarkable heterogeneity in any of the above comparisons (Table [4](#Tab4){ref-type="table"}, all I^2^ \< 50.0%, *P* value of heterogeneity \> 0.1). Thus, a fixed-effects model was applied. We also conducted both Begg's test and Egger's test to assess the presence of publication bias. As shown in Table [4](#Tab4){ref-type="table"}, the *P* values of Begg's test and Egger's test were larger than 0.05 in all genetic models, indicating the absence of large publication bias. We showed Begg's funnel plot and the association between the *MTHFR* rs1801131 polymorphism and colorectal polyp risk under the CC vs. AA model in Fig. [5](#Fig5){ref-type="fig"}a. Additionally, similar pooled RRs were detected in our sensitivity analysis under other genetic models (Fig. [5](#Fig5){ref-type="fig"}b for CC vs. AA model of *MTHFR* rs1801131; other data not shown), suggesting the reliability of pooling outcomes.Table 4The assessment of heterogeneity and publication biaspolymorphismComparisonI^2^*P* valueModelBegg's testEgger's testz*P*t*P*rs1801133allele T vs. allele C0.0%0.736Fixed0.690.4920.460.651TT vs. CC0.0%0.799Fixed0.900.3670.750.463CT vs. CC0.0%0.705Fixed0.790.428−0.410.685CT + TT vs. CC0.0%0.725Fixed0.110.916−0.020.984TT vs. CC + CT0.0%0.790Fixed0.730.4630.700.492carrier T vs. carrier C0.0%0.999Fixed0.320.7510.270.787rs1801131allele C vs. allele A9.6%0.354Fixed1.160.2451.410.195CC vs. AA14.3%0.311Fixed1.520.1281.960.085AC vs. AA0.0%0.800Fixed0.450.655−0.250.807AC + CC vs. AA0.0%0.623Fixed1.340.1800.640.541CC vs. AA+AC8.3%0.366Fixed1.520.1282.170.061carrier C vs. carrier A0.0%0.918Fixed0.980.3251.040.327FIG. 5Begg's funnel plot and sensitivity analysis for *MTHFR* rs1801131 polymorphism and colorectal polyp risk under the CC vs. AA model. **a** Begg's funnel plot; **b** Sensitivity analysis

Discussion {#Sec13}
==========

Several meta-analyses have reported the role of *MTHFR* polymorphisms in the susceptibility to colorectal cancer (CRC) and adenoma. For example, in 2005, Kono, S. and colleague included a total of 16 case-control studies for a meta-analysis on the genetic relationship between *MTHFR* rs1801133 polymorphism and the risk of colorectal cancer and reported the potential role of the TT genotype in reduced CRC susceptibility \[[@CR11]\]. In 2007, Huang, Y. et al. performed another meta-analysis to report that *MTHFR* rs1801133 and rs1801131 polymorphisms may confer reduced susceptibility to CRC patients \[[@CR6]\]. In 2011, Zacho, J. et al. enrolled 75,000 cases and 93,000 controls for a meta-analysis of the association between the *MTHFR* rs1801133 polymorphism and overall cancer susceptibility and found that the TT genotype of *MTHFR* rs1801133 was associated with a decreased risk in CRC patients with lifelong hyperhomocysteinemia and hence hypomethylation \[[@CR33]\]. Recently, data from another updated meta-analysis with 37,049 cases and 52,444 controls from 91 case-control studies suggested that the *MTHFR* rs1801133 polymorphism was related to a reduced risk of CRC, particularly in the Asian population \[[@CR34]\]. These data supported the protective effect of *MTHFR* polymorphism, especially rs1801133, on CRC risk. However, inconsistent results regarding the role of the *MTHFR* polymorphism in the risk of colorectal adenoma were observed in the quantitative synthesis.

Meta-analysis of Huang, Y. et al. revealed that *MTHFR* rs1801133 and rs1801131 polymorphisms may have no increasing or decreasing effect on the risk of colorectal adenoma patients \[[@CR6]\]. In addition, Edwards, T. L. and colleagues included 2551 colorectal adenoma cases and 3285 controls in the Caucasian population and performed genome-wide association studies (GWASs) to identify potential susceptibility factors, but *MTHFR* polymorphisms did not reach a genome-wide significant *P* value \[[@CR35]\]. However, Kono, S. and colleagues reported that the TT genotype of the *MTHFR* rs1801133 polymorphism may be associated with high susceptibility to colorectal adenoma in patients with poor folate status \[[@CR11]\]. In 2016, Montazeri, Z. and colleague conducted a systematic review and meta-analyses to assess the association between 37 polymorphisms within 26 genes and colorectal adenoma risk and observed the potential genetic role of *the MTHFR* rs1801133 polymorphism, but with a relatively lower statistical power \[[@CR12]\].

In this study, we intended to reassess the role of the *MTHFR* rs1801133 polymorphism in the susceptibility to colorectal adenomas in terms of colorectal polyps by means of a meta-analysis containing twenty-three case-control studies with 8339 cases and 17,731 controls. Our findings did not show any association between the *MTHFR* rs1801133 polymorphism and the risk of colorectal adenomatous polyps or hyperplastic polyps.

Moreover, we performed another meta-analysis of ten case-control studies with 2969 cases and 3527 controls and found that the C/C genotype of the *MTHFR* rs1801131 polymorphism has a significant influence on an increased risk of colorectal polyps in the UK population. The A to C substitution in exon seven of *MTHFR* gene-induced abnormal enzymatic activity, homocysteine or folate level and DNA methylation/synthesis may be implicated in this process. It is noteworthy that, based on the requirement of meta-analysis for the enrolled case-control number, we evaluated only the subgroup analysis data with at least three case-control studies. Therefore, the subgroup analysis data for Australia, the USA, Korea, and Japan, with one or two case-control studies, exhibits very limited statistical power. We still cannot exclude the potential effect of the *MTHFR* rs1801131 polymorphism in colorectal polyp patients of other regions.

The case-control studies in our analysis were screened by fulfilling our strict selection criteria. All the studies exhibit high quality. In addition, we observed no heterogeneity in any of the Mantel-Haenszel statistics and excluded the large publication bias. Moreover, the stability of the statistical outcomes was detected by the sensitivity analysis. Nevertheless, we are also aware of several limitations. The main problem is the small sample size in the included case-control studies. For example, only one case-control study analyzed the correlation between the *MTHFR* rs1801131 polymorphism and hyperplastic polyp risk \[[@CR14]\]. Second, only two SNPs were measured in our study. We did not study the genetic effects of other SNPs, combination with other genes, or the levels of folate, homocysteine, vitamin B12 and colorectal polyp risk. Third, hyperplastic and adenomatous polyps have complex and different etiologies. As a genetic effect of *MTHFR* rs1801133 and rs1801131 polymorphisms has been suggested in the susceptibility to colorectal cancer \[[@CR6], [@CR11], [@CR33], [@CR34]\], additional confounding factors such as smoking, drinking, age, sex, and patient features should be adjusted for further investigation of the *MTHFR* variants in the malignant conversion from colorectal polyp.

Conclusion {#Sec14}
==========

Taken together, our findings conclude that *MTHFR* rs1801131, rather than rs1801133, is more likely to be associated with an increased susceptibility to colorectal polyps in the UK population. Additionally, the C/C genotype of *MTHFR* rs1801131 may confer an increased susceptibility to patients with colorectal polyps in the UK region. However, this conclusion merits further confirmation with a larger sample size.
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CI

:   Confidence interval

CRC

:   Colorectal cancer

FAP

:   Familial adenomatous polyposis

GWAS

:   Genome-wide association studies

HWE

:   Hardy-Weinberg Equilibrium

MTHFR

:   Methylenetetrahydrofolate reductase

NOS

:   Newcastle-Ottawa Scale

RRs

:   Risk ratios
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